Sexually Transmitted Disease Diagnostics Market
Number of pages: 100 | Report Format: PDF | Published date: 17 February, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 14 billion |
|
Revenue forecast in 2030 |
US$ 22.74 billion |
|
Growth Rate |
CAGR of 5.4% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments covered |
Disease Type, Device Type, End User, and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global sexually transmitted disease diagnostics market was valued at US$ 14 billion in 2021 and is expected to register a revenue CAGR of 5.4% to reach US$ 22.74 billion by 2030.
Market Fundamentals
Sexually transmitted diseases spread through unprotected sexual interaction. Blood, semen, vaginal fluid, and other bodily fluids can carry infection-causing bacteria, viruses, or parasites. These infections can occasionally spread non-sexually, such as when women give birth, receive blood transfusions, or share needles.
Sexually transmitted infections (STDs) put individuals at risk for lifelong health problems and impact public health. The likelihood of limiting the disease's impact grows with early and prompt STD diagnosis. STDs include gonorrhea, syphilis, chlamydia, genital herpes, and human papillomavirus (HPV) can cause severe and occasionally lifelong problems if left untreated. Infertility, birth problems, mental retardation, cancer, heart illness, bone deformities, blindness, and even death are among these side effects. Diagnosis is necessary for managing and treating STDs, and numerous diagnostic tests are available. Chlamydia and gonorrhea, for instance, can be identified using urine or blood testing. However, herpes and HIV can be identified with swab tests. It is crucial to remember that multiple tests must be used to accurately diagnose sexually transmitted diseases because some STDs can produce false-negative findings.
Additionally, those who are susceptible to infection must undergo routine testing. Developing techniques for early identification and treatment is critical as the prevalence of sexually transmitted illnesses rises. Rapid testing techniques have been developed that provide a precise diagnosis and stop the spread of infection. These tests can now be obtained easily and performed in the patient's home. Medical practitioners are now faster than ever at diagnosing and treating infections due to new technology. Advancements in medical technology have also enhanced the ability for patients to receive timely, accurate findings. Patients can receive the best care possible by being diagnosed swiftly and accurately with the most recent medical technologies.
[657567]
Market Dynamics
The sexually transmitted diseases diagnostics market is expected to grow significantly over the forecast period. This growth is due to the rising prevalence of sexually transmitted diseases worldwide, increased awareness, and the growing availability of diagnostic tests. Technological advances have enabled the development of more effective and accurate diagnostic tests, enhanced the accuracy of diagnosis, and reduced the risk of misdiagnosis. Furthermore, the introduction of point-of-care diagnostic tests has increased the availability of diagnostics and improved accessibility. Additionally, the increasing focus on preventive healthcare drives the demand for early diagnosis and treatment. Governments are also taking initiatives to reduce the prevalence of sexually transmitted diseases, which is expected to drive market growth further. Some constraints to the growth of the global sexually transmitted disease diagnostics market are the high social stigma, the high cost of the detection equipment, and the lack of precision.
The global sexually transmitted disease diagnostics market has been analyzed from four perspectives: Disease Type, Device Type, End User, and Region.
Sexually Transmitted Disease Diagnostics Market by Disease Type
[757464]
Based on disease type, the global sexually transmitted disease diagnostics market has been subdivided into chlamydia, syphilis, hepatitis b, HIV/AIDS, human papillomavirus (HPV), gonorrhea, and others.
STDs caused by chlamydia dominate the global sexually transmitted disease diagnostics market. It is because it is the most commonly occurring sexually transmitted infection caused by bacteria. However, due to the rising frequency of syphilis infections worldwide, the diagnosis of sexually transmitted illnesses brought on by syphilis is on the rise and projected to account for over 20% of the market by 2022, growing at a robust revenue CAGR.
Sexually Transmitted Disease Diagnostics Market by Device Type
Based on device type, the global sexually transmitted disease diagnostics market has been divided into laboratory and point-of-care devices.
The laboratory devices include thermal cyclers—PCR, flow cytometers, Enzyme-linked Immunosorbent Assay (ELISA), and others. PCR for STD diagnosis is expected to grow with a lucrative revenue CAGR over the forecast period. It is because of the most accurate results provided by PCR testing devices. The point of care testing devices segment includes phone chips and portable/benchtop/rapid diagnostic kits. Technological advancements in point of care testing equipment produce results that are more accurate and reliable. The portable POC testing device subsegment market is expected to grow significantly in the forecast period.
Sexually Transmitted Disease Diagnostics Market by End User
Based on end users, the global sexually transmitted disease diagnostics market has been divided into laboratory testing, and point of care testing. The most frequent method used to diagnose sexually transmitted diseases (STDs) worldwide is laboratory testing. Laboratory tests are widely used and have a high level of accuracy, so people tend to place more trust in them. Additionally, there have been ongoing product developments in molecular diagnostics, which is one of the key drivers behind the expansion of the laboratory testing market. More product introductions enable laboratories to install instruments or equipment as necessary. For instance, with authorization from the European Commission, Qiagen Inc. released NeuMoDxHSV 1/2 Quant Assay in May 2022 for the quantification and distinction of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2).
Sexually Transmitted Disease Diagnostics Market by Region
Based on region, the global sexually transmitted disease diagnostics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
The sexually transmitted disease diagnostics market in North America is growing rapidly. The prevalence of STDs in the region has increased exponentially in recent years, requiring better diagnostic tools to help detect and manage these diseases. To meet the growing need for better diagnostics, many companies are investing in innovative solutions such as molecular diagnostics, which can accurately identify the presence of STDs. Additionally, the market for point of care diagnostics is expected to grow as it provides a convenient and cost-effective way for patients to access testing. With increasing awareness of the importance of diagnosis and treatment of STDs, the North American market for STD diagnostics is expected to grow significantly in the years to come.
Competitive Landscape
Some of the prominent players operating in the global sexually transmitted disease diagnostics market are:
Strategic Developments
The global sexually transmitted disease diagnostics market is expected to grow at a revenue CAGR of 5.4% in the forecast period from 2022 to 2030.
Abbott Laboratories, DiaSorin S.p.A, Siemens AG, Hologic, Inc., and Roche Holdings AG, are a few key players in the global sexually transmitted disease diagnostics market.
The laboratory testing segment dominates the global sexually transmitted disease diagnostics market.
Asia Pacific region is expected to have the highest global sexually transmitted disease diagnostics market growth in the forecast period.
The global sexually transmitted disease diagnostics market was valued at US$ 14 billion in 2021.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst